论文部分内容阅读
目的:分析长江流域6城市样本医院使用胸腺肽类制剂的情况及变化趋势,并作安全性评估。方法:利用上海市食品药品监督管理局科技情报所医院用药分析系统提供的2005～2007年6城市180所样本医院胸腺肽类制剂用药信息,对用药金额、市场排序、DDDs等进行统计分析。结果:胸腺肽类购药金额整体上逐年上升,仅南京地区呈现下降,6城市胸腺肽类金额排序均在领先药品销售的前20位,尤其杭州地区2007年排序至第1位。胸腺五肽和胸腺肽α1占据优势。结论:由于胸腺肽高端产品具有纯度高,生物活性强、安全性好,在长江流域6城市样本医院使用中已占有优势,逐步淘汰老产品,发展生产高端产品成为今后市场发展的趋势。
OBJECTIVE: To analyze the situation and trend of thymopeptide preparations in 6 cities in the Yangtze River Basin and to evaluate safety. Methods: Using the information of thymopeptide preparations in 180 sample hospitals in 6 cities from 2005 to 2007 provided by the Hospital Drug Analysis System of Shanghai Institute of Scientific and Technical Information of Shanghai Municipal Food and Drug Administration, statistical analysis was conducted on the amount of medication, market order and DDDs. Results: The total amount of thymopeptide purchased increased year by year, only the Nanjing area showed a decline. The amount of thymus peptides in the six cities ranked the top 20 in the sales of leading drugs. In particular, Hangzhou ranked the first place in 2007. Thymopentin and thymosin α1 dominate. Conclusion: The high-end products of thymosin have the advantages of high purity, strong biological activity and good safety. They occupy an advantage in the use of sample hospitals in 6 cities of the Yangtze River Basin, and phasing out of old products and development of high-end products have become the trend of future market development.